Navigation Links
TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
Date:5/26/2009

SAN DIEGO, May 26 /PRNewswire/ -- TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that Phase 1 clinical results from studies of TRC105 and TRC102 in patients with advanced cancer will be presented at the American Society of Clinical Oncology annual meeting this May 28th and 29th in Orlando, Florida. Both programs target unique pathways with the potential for broad application to a wide variety of cancer types.

TRC105 is a monoclonal antibody that binds CD105 (endoglin), a membrane receptor on endothelial cells that is required for angiogenesis. By inhibiting new blood vessel formation, the antibody is expected to have activity against a wide variety of solid tumors that rely on angiogenesis to grow and metastasize. CD105 is also expressed on cancer stem cells.

TRC102 is a small molecule inhibitor of base excision repair that reverses resistance to commonly used antimetabolite and alkylating agent chemotherapies. The molecule is currently being studied as an oral agent in combination with pemetrexed (Alimta(R)) and as an intravenous agent in combination with temozolomide (Temodar(R)).

"TRACON remains on schedule to deliver three Phase 2-ready assets in 2009 including two monoclonal antibodies," commented Charles P. Theuer MD PhD, President and CEO of TRACON Pharmaceuticals. "We are currently engaged in manufacturing and clinical development activities to support comprehensive Phase 2 programs."

The presentation details are as follows:

    TRC105
    Abstract Title: Phase 1 study of TRC105 (anti-CD105 (endoglin) antibody)
    therapy in patients with advanced refractory cancer
    Presenter: Lee Rosen, MD, Premiere Oncology - Los Angeles
    Date and Time: Friday, May 29, 2009, 2:00 PM - 6:00 PM
    Session Title: Developmental Therapeutics
    Session Type: Poster Discussion
    Abst
'/>"/>
SOURCE TRACON Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
2. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
3. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
4. Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
5. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
6. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting
7. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
8. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
9. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
10. Transcept Pharmaceuticals to Report First Quarter 2009 Results
11. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Trade Commission (ITC) issued its final decision in the case ... issued on December 23, the ITC ruled in favor of ... invalid. BMC President, James Xu called ... the ITC,s decision in this case. This victory for us ... beginning on the key patents in the case. ResMed chose ...
(Date:12/24/2014)... Wis. , Dec. 23, 2014 PuraMed ... marketer of over-the-counter (OTC) medicinal and healthcare products, announced ... of MigraPure® H, a hemp-based, advanced headache relief product, ... dispensaries in Colorado , ... . With the MigraPure H Advanced headache ...
(Date:12/24/2014)...   Synageva BioPharma Corp. (NASDAQ: ... products for rare disorders, today announced validation by ... Authorization Application (MAA) for sebelipase alfa for LAL ... for accelerated assessment, which has the potential to ... The MAA, and the Biologics License Application ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
(Date:12/26/2014)... (PRWEB) December 26, 2014 The Biofeedback ... place March 24-28, 2015 in Rome, Italy and is ... includes workshops on a wide variety of ... well as peak performance training in athletes. The scientific ... the world. , Biofeedback monitoring allows clients to see ...
(Date:12/26/2014)... December 26, 2014 DW-InductionHeating.com (DaWei Induction ... designing, researching and developing, producing and marketing of a ... the business announces their new series of induction ... of the company, induction brazing refers to ... special filler material and heat. The manager says that ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... and Market Analysis to 2023” focuses on the ... commercial opportunities in the colorectal cancer market. Stivarga ... treatment of colon or rectal cancer. Boehringer Ingelheim ... inhibitor, for the treatment of refractory CRC in ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company ... collection of discounted prom dresses, most of which are ... of the company, the promotion is valid until Jan. ... expand the UK market. , The prom dresses in ... and styles: A-line strapless, empire strapless chiffon, one shoulder, ...
(Date:12/25/2014)... 2014 When head lice hits a home ... frenzy to get rid of it while keeping it from ... Gables now have the solution right in their neighborhood: ... Lice Troopers provides full spectrum head lice screening and treatment ... including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2
... Cipla has offered to manufacture an antiviral drug for ... by Glaxo Smithkline. It has already made Tamiflu in its ... well known and popular as Tamiflu has but is cheaper ... Hameid, CEO of Cipla in a press release said:‘‘Zanamivir is ...
... as the first most common cause for death in ... stress echocardiography that can help predict life-threatening heart problems ... conducted among a group of diabetic women aged between ... type of stress test for suspected coronary disease that ...
... form chronic back pain, an increasing attention is being ... study has established that chiropractic care produces significantly // ... underwent the therapy had higher pain relief and satisfaction ... medical care. , ,The study has been conducted ...
... detected by using a hand-held scope called VELscope, which has ... by National Institute of Dental Craniofacial Research. The devise emits ... white light in detection of cancerous lesions in the mouth. ... oral cancer as better treatment is achieved when oral cancer ...
... National Laboratory are studying the biopolymer structural dynamics of ... new theory on protein folding unfolds the mystery of ... to diseases and the study is to be published ... Sciences. , ,The researchers used a technique called ...
... Britain can look forward to some relief, as a cannabis-based ... time, following approval from the Home Office for its importation ... be able to obtain an unlicensed, cannabis-based medicine on prescription ... it is yet to be licensed in the UK. The ...
Cached Medicine News:Health News:Cipla In India Can Manufacture Drug For Bird Flu 2Health News:Cipla In India Can Manufacture Drug For Bird Flu 3Health News:A Simple Test To Detect Heart Disease In Women Can Be Lifesaving 2Health News:Back Pain Can Now Be Cost-Effectively Treated By Chiropractic Care 2Health News:Relief For British MS Patients: Cannabis-Based Oral Spray 2
Bard Coude-Tip Latex Urethral Catheter, Two Eyes (Tiemann Model)...
Red Latex Bardex I.C. Foley 2-Way Catheter (Council Model)...
The BARDEX I.C. Catheter represents Bard's newest technology in providing protection against NUTI....
Used for injection into urethral strictures, bladder neck contracture, and the bladder wall. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: